FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant

A hollow-fiber dialyzer held upright in a clamp on a short pole, its clear housing showing fine fibers, with tubing arching from its top cap.

The Food and Drug Administration (FDA) on Nov. 13 approved Gazyva (obinutuzumab), the first drug specifically for primary membranous nephropathy, after 36% complete remission versus 6% with tacrolimus.

A randomized trial found dapagliflozin improved eGFR slope in heart transplant recipients, and pegcetacoplan kept proteinuria down through one year in C3 glomerulopathy.

The weekly innovation roundup for nephrology, published every Sunday for the week before; every item links to its sources. Latest nephrology news · All specialties

Latest news

Tagged nephrology, from the daily briefing

  1. FDA approves obinutuzumab as the first drug for primary membranous nephropathy after 36% reached remission versus 6% on tacrolimus
  2. National Kidney Foundation workshop says measuring urine albumin is generally preferred over total urine protein
  3. Pegcetacoplan keeps a 67% proteinuria reduction through week 52 in C3 glomerulopathy and immune-complex MPGN

See all the latest news